We are live on ! Find out more
INM icon

InMed Pharmaceuticals
INM

14 hedge funds and large institutions have $334K invested in InMed Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,702% more capital invested

Capital invested by funds: $18.6K → $334K (+$316K)

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

75% more funds holding

Funds holding: 8 → 14 (+6)

0.72% more ownership

Funds ownership: 0.04% → 0.76% (+0.72%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
14
Holders Change
+6
Holders Change %
+75%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$248K
2
AC
Armistice Capital
New York
+$100K
3
Renaissance Technologies
Renaissance Technologies
New York
+$18.9K
4
Citadel Advisors
Citadel Advisors
Florida
+$16.5K
5
TSS
Two Sigma Securities
New York
+$6.26K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$18.3K
2
UBS Group
UBS Group
Switzerland
-$48
3
Osaic Holdings
Osaic Holdings
Arizona
-$10
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$213K +$248K +25,597 New
AC
2
Armistice Capital
New York
$85.7K +$100K +10,298 New
Renaissance Technologies
3
Renaissance Technologies
New York
$16K +$18.9K +1,945 New
Citadel Advisors
4
Citadel Advisors
Florida
$14.1K +$16.5K +1,700 New
TSS
5
Two Sigma Securities
New York
$5.36K +$6.26K +645 New
Qube Research & Technologies (QRT)
6
Qube Research & Technologies (QRT)
United Kingdom
$83 +$97 +10 New
TWC
7
TD Waterhouse Canada
Ontario, Canada
$43 – – –
Bank of America
8
Bank of America
North Carolina
$42 +$49 +5 New
ASN
9
Advisory Services Network
Georgia
$25 +$29 +3 New
Osaic Holdings
10
Osaic Holdings
Arizona
$15 -$10 -1 -33%
AWM
11
AllSquare Wealth Management
New York
$9 – – –
FDCDDQ
12
Federation des caisses Desjardins du Quebec
Quebec, Canada
$8 – – –
National Bank of Canada
13
National Bank of Canada
Quebec, Canada
$5 – – –
GRP
14
Global Retirement Partners
California
$2 – – –
Toronto Dominion Bank
15
Toronto Dominion Bank
Ontario, Canada
$1 – – –
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
– -$18.3K -1,329 Closed
UBS Group
17
UBS Group
Switzerland
– -$48 -3 Closed

INM Hedge Fund Activity: Q4 2023 in Review

14 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q4 2023, worth a combined $334K — up 1,702% from $18.6K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new INM positions and 2 closed out — a net gain of 6 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $248K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $18.3K sold.

  • 14 institutional investors held InMed Pharmaceuticals (INM) as of Q4 2023, up from 8 in Q3 2023.
  • Funds reported $334K of InMed Pharmaceuticals stock for Q4 2023, up 1,702% quarter-over-quarter.
  • 8 funds opened new InMed Pharmaceuticals positions in Q4 2023 and 2 closed out, a net change of +6 holders.
  • The largest InMed Pharmaceuticals buyer in Q4 2023 was Sabby Management, an estimated $248K added.
  • The largest InMed Pharmaceuticals seller in Q4 2023 was Susquehanna International Group, an estimated $18.3K sold.

Based on aggregated 13F filings for Q4 2023.